Correlation Between Enorama Pharma and Kancera AB
Can any of the company-specific risk be diversified away by investing in both Enorama Pharma and Kancera AB at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Enorama Pharma and Kancera AB into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Enorama Pharma AB and Kancera AB, you can compare the effects of market volatilities on Enorama Pharma and Kancera AB and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Enorama Pharma with a short position of Kancera AB. Check out your portfolio center. Please also check ongoing floating volatility patterns of Enorama Pharma and Kancera AB.
Diversification Opportunities for Enorama Pharma and Kancera AB
0.58 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Enorama and Kancera is 0.58. Overlapping area represents the amount of risk that can be diversified away by holding Enorama Pharma AB and Kancera AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Kancera AB and Enorama Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Enorama Pharma AB are associated (or correlated) with Kancera AB. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Kancera AB has no effect on the direction of Enorama Pharma i.e., Enorama Pharma and Kancera AB go up and down completely randomly.
Pair Corralation between Enorama Pharma and Kancera AB
Assuming the 90 days trading horizon Enorama Pharma AB is expected to generate 0.3 times more return on investment than Kancera AB. However, Enorama Pharma AB is 3.31 times less risky than Kancera AB. It trades about -0.1 of its potential returns per unit of risk. Kancera AB is currently generating about -0.12 per unit of risk. If you would invest 388.00 in Enorama Pharma AB on September 1, 2024 and sell it today you would lose (42.00) from holding Enorama Pharma AB or give up 10.82% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 95.65% |
| Values | Daily Returns |
Enorama Pharma AB vs. Kancera AB
Performance |
| Timeline |
| Enorama Pharma AB |
| Kancera AB |
Enorama Pharma and Kancera AB Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Enorama Pharma and Kancera AB
The main advantage of trading using opposite Enorama Pharma and Kancera AB positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Enorama Pharma position performs unexpectedly, Kancera AB can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kancera AB will offset losses from the drop in Kancera AB's long position.| Enorama Pharma vs. Kancera AB | Enorama Pharma vs. Cyxone AB | Enorama Pharma vs. Lidds AB | Enorama Pharma vs. Cantargia AB |
| Kancera AB vs. Combigene AB | Kancera AB vs. Cantargia AB | Kancera AB vs. Fingerprint Cards AB | Kancera AB vs. Spectrumone publ AB |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Complementary Tools
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| CEOs Directory Screen CEOs from public companies around the world |